(P<0.01)1. A similar trend was revealed in immunocompetent patients (an older, chronically sun-exposed population) but with lower prevalence of p53 immunoreactivity: 25% of uninvolved skin samples. 0%0 of viral warts. 25% of keratoses. 53% of intraepidermal carcinomas and 53% of squamous cell carcinomas. These differences were not statistically significant. Morphologically. p53 immunoreactivity strongly associated with areas of epidermal dysplasia and the abundance of staining correlated positively with the severity of dysplasia. These data suggest that p53 plays a role in skin carcinogenesis and is associated with progression towards the invasive state. No correlation was observed between accumulated p53 and the presence of human papillomavirus (HPV) DNA in any of the lesions. Single-strand conformational polymorphism analysis (exons 5-8) was used to determine the frequency of mutated p53 in 28 malignancies with varying degrees of immunopositivity. p53 mutations were found in 5 9 (56%) malignancies with p53 staining in > 50%0 of cells. reducing to 1 6 (17%) where 10-50% of cells were positively stained and none where <10% of cells were stained. These data imply that factors other than p53 gene mutation play a part in accumulation of p53 in skin cancers.
The p53 gene encodes a 53 kDa phosphoprotein that acts as a transcription factor and has tumour-suppressor functions. The wild-type gene product also has the ability to induce growth arrest and or apoptosis in response to DNA injury. preventing replication of genomes that have suffered DNA damage (Kastan et al.. 1991 : Hartwell, 1992 : Lane. 1992 Unger et al.. 1992 : Clark et al.. 1993 Hall et al., 1993) . Mutations in the p53 gene are considered to play a significant part in the development of many human malignancies: a high frequency of mutation is observed in most of the common forms of human cancer and there are elevated rates of malignancy in patients with Li-Fraumeni syndrome (in which there is an inherited p53 gene mutation) and in genetically engineered, p53-deficient mice (Baker et al., 1989; Nigro et al.. 1989; Srivastava et al.. 1990; Hollstein et al.. 1991 : Donehower et al.. 1992 Purdie et al.. 1994) . A number of oncogenic viral proteins can also form complexes with wildtype p53. initiating gene inactivation by mechanisms other than mutational loss of function (Scheffner et al., 1990; Yew & Berk. 1992 ; Debbas & White. 1993 : Moran. 1993 ). Most of the mutations observed in p53 are thought to induce conformational changes in the protein product. increasing its halflife and rendering it detectable by immunocytochemical techniques (Milner & Cook. 1986; Gannon et al., 1990; Milner & Medcalf. 1991 : Montenarh. 1992 : WynfordThomas. 1992 .
Renal allograft recipients (RARs) manifest a greatly increased susceptibility to cutaneous malignancy, with squamous cell carcinoma (SCC) occurring commonly, especially in patients with long graft life or high sun exposure (Shuttleworth et al., 1987 : Alloub et al.. 1989 Benton et al., 1992 (Streilein, 1991) and human papillomavirus (HPV) infection (Rudlinger et al., 1986; Barr et al., 1989 : Benton et al.. 1992 Stark et al.. 1994) , little is known of the associated genetic events and whether these may differ in RARs and immunocompetent patients (ICPs). To our knowledge. there have been no major studies in which the role of p53 in the development of cutaneous lesions in RARs has been considered, although p53 mutations have been reported to occur in IECs and SCCs from ICPs (Brash et al.. 1991; Gusterson et al.. 1991; Pierceall et al., 1991; McGregor et al.. 1992 : Burns et al., 1993 Campbell et al., 1993a, b) .
In this study we have employed immunocytochemical techniques to compare the prevalence of p53 accumulation in premalignant and malignant cutaneous lesions from both RARs and ICPs. Single-strand conformational polymorphism (SSCP) analysis was also employed to determine the relationship between positive immunocytochemistry and p53 gene mutations. The relationship between p53 expression and the HPV satus of the lesions was also considered since it has been reported that viral oncoproteins may play a part in p53 inactivation in other HPV-associated malignancies (Scheffner et al., 1990 (Scheffner et al., , 1991 (Scheffner et al., , 1992 Werness et al.. 1990; Crook et al.. 1991 Crook et al.. , 1992 DNA extraction and HPV detection Frozen tissue was minced in lysis buffer (50 mM Tris, 50 mM EDTA, 100 mM sodium chloride, 5 mM DTT, 1% SDS 1.5 mg ml-1 proteinase K) then incubated at 3TC overnight. DNA extraction was carried out using a standard phenol-chloroform extraction technique (Sambrook et al.. 1989) . Two methods were employed to screen for the presence of HPV DNA (Stark et al., 1994) . Southern analysis, using mixed HPV probes at low hybridisation (Tm -40°C) and washing stringency (Tm -35C), was used to detect common cutaneous and epidermodysplasia verruciformis (EV)-related types. The polymerase chain reaction (PCR) was used to detect specific HPV types 1, 2, 5, 8, 6, 11. 16 and 18 (Arends et al., 1991; Stark et al., 1994) .
Histopathologv
The skin lesions were classified as follows: viral warts (VWs) exhibited symmetry, papilliferous architecture and koilocytic change; verrucous keratoses (VKs) displayed the architecture of warts but lacked definitive cytological features of viral infection; actinic keratoses (AKs) showed basal budding and basal hypermelanosis (degrees of dysplasia were assessed in both types of keratosis); intraepidermal carcinoma (IECs) showed either full-thickness dysplasia or severe dysplasia and acantholysis of the basal layer, invasive squamous cell carcinoma (SCC) showed dermal invasion (Blessing et al., 1989) .
Immunoci tochemistry
Immunocytochemistry was performed on 3 fLm sections of PLPD-and formalin-fixed tissue using the mouse anti-p53 monoclonal antibodies MAb Do-7 (Vojtesek et al., 1992) and PAb 1801 (Banks et al., 1986 ) and a standard ABC horseradish peroxidase (HRP) technique (Dako, High Wycombe, Bucks, UK) as previously described (Purdie et al., 1991) . Formalin-fixed tissue was treated with MAb Do-7 (1:100 dilution, overnight incubation) only, whereas PLPD-fixed material was treated with MAb Do-7 and PAb 1801 (1:100 dilution. 1 h incubation). Each section was scored by two independent observers and the extent of staining recorded on the following graded scale: 1 = <10%, 2 = 10-50% and 3 = > 50% of cells in a lesion showing positive nuclear staining. Sections were recorded as positive when immune precipitate was visible in > 10% of cells in the lesion, i.e. grades 2 and 3 only. Lesions with grade 1 score were considered to be negative. The histological localisation of accumulated p53 within each lesion was also noted. Figures I and 2) . In both populations, over 50% of SCCs exhibited p53 immunoreactivity in > 10% of cells (grades 2 and 3). Overall, the number of lesions exhibiting accumulated p53 and the grade of staining within these lesions correlated positively with the degree of dysplasia present. In RARs, significantly more IECs and SCCs demonstrated accumulated p53 than either uninvolved sun-exposed skin (US) (X: test, P<0.05) or VWs (X: test. P<0.01). A similar trend was revealed in ICPs, although a lower proportion of cases were stained positive for p53. However, the differences between SCCs or IECs and US in ICP were not statistically significant.
Distribution of accumulated p53
In both RARs and ICPs, immunostaining of lesions was confined to nuclei of dysplastic epithelial cells and was most abundant in areas of severe dysplasia (Figure 2a) . Within K and IEC lesions. staining was generally strongest in basal epithelial layers, particularly at sites of basal budding where dysplastic changes were most severe (Figure 2a and b) . This was particularly notable in Ks exhibiting actinic features. In dysplastic Ks and IECs, acantholysis and suprabasal clefting were also observed to correlate with strong p53 staining. In tissue sections that contained skin appendages, the specialised lining cells were always negative and staining was confined to the surrounding dysplastic cells (Figure 2c ). While the majority of SCCs showed accumulated p53, there was a tendency for greater positivity to occur in less welldifferentiated lesions (Figure 2d) three HPV-positive malignancies and one HPV-negative malignancy.
p53 accumulation and progression in cutaneous carcinogenesis In this study we have demonstrated the presence of accumulated p53 in over 50% of cutaneous SCCs from both RARs and ICPs suggesting that p53 may play a role in skin carcinogenesis in both populations. This detection level is in broad agreement with previously reported results for SCC in ICPs in which it has ranged from 15% to 56% of lesions (Gusterson et al., 1991; McGregor et al., 1992; Ro et al.. 1992) . A striking feature of our study was the increase in prevalence and extent of staining which occurred as lesions progressed through the histological spectrum of neoplasia. Indeed, there was a close correlation between the extent of staining in these lesions and the severity of dysplasia. These results strongly suggest that in skin carcinogenesis, in both RARs and ICPs, accumulation of p53 represents an important step in malignant progression. This hypothesis is supported by recent studies of skin carcinogenesis in p53 null mice, in which inactivation of p53 specifically associates with progression of benign papillomas to SCCs (Kemp et al., 1993) . It is important to note, however, that the occurrence of p53 immunoreactivity does not always equate with acquisition of the malignant state since in ICPs accumulated p53 can be demonstrated in solar keratoses, of which only a small proportion progress to invasive carcinoma (Marks et al., 1986 (Scheffner et al., 1990; Werness et al., 1990) . From observations in anogenital cancers it has been proposed that p53 inactivation occurs either by complexing of wild-type p53 with such viral oncoproteins or, in the absence of virus, by mutational loss of gene function (Crook et al., 1991 (Crook et al., , 1992 Scheffner et al., 1991 Scheffner et al., . 1992 . This concept, however, remains controversial, and other workers have failed to confirm these suggestions (Busby-Earle et al., 1993; Cooper et al., 1993) . We have recently reported the prevalence of HPV in cutaneous lesions from RARs (Stark et al., 1994) and suggested that the mechanism by which HPV contributes to skin carcinogenesis may differ from that proposed for anogenital cancer. The present study confirms our previous findings in that we (Pierceall et al., 1991; Ro et al.. 1992; Campbell et al., 1993a, b) . With one exception, these mutations occurred in exons 5 and 7, in keeping with the suggestion that these exons contain mutational hotspots for most human malignancies (Brash et al., 1991; Hollstein et al., 1991; Pierceall et al., 1991; Campbell et al., 1993a; Levine, 1993) . Molecular analysis of p53 mutations has previously suggested that the pattern of nucleotide alterations may be tissue dependent and related to the type of mutagenic agent involved (Harris, 1991; Vogelstein & Kinzler, 1992) . For instance, CC to rT double-base changes are almost exclusively associated with UV-induced DNA damage (Brash et al., 1991) . It is of interest, therefore, that the SCC in our series that was sequenced was found to contain a C-T transition at the codon 248 mutational hotspot, implicating UV radiation in its genesis.
p53 immunocytochemical detection and gene mutations Immunocytochemistry has been proposed as a rapid and simple means of identification of p53 gene mutations. In the majority of tumours. good correlation has been observed between the presence of immunocytochemically stable p53 and gene mutations determined by sequencing or other methods (Gannon et al., 1990; Iggo et al., 1990; Bodner et al., 1992) . However, it is also recognised that immunocytochemically detectable levels of wild-type p53 may occur in response to DNA injury, and that some p53 mutations do not result in immunocytochemical demonstration of p53 protein (Bodner et al.. 1992; Oliner et al., 1992; WynfordThomas, 1992; Hall et al.. 1993 , Lane. 1993 
